Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Bortezomib and Romidepsin in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Indolent B-cell Lymphoma, Peripheral T-cell Lymphoma or Cutaneous T-Cell Lymphoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Virginia Commonwealth University
ClinicalTrials.gov Identifier:
NCT00963274
First received: August 20, 2009
Last updated: December 7, 2016
Last verified: December 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2016
  Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)